Opus Genetics reported earnings of -$ 0.46 per IRD share on Nov 10, 2026, beating analysts' expectations by
| Report Date | Nov 10, 2026 |
|---|---|
| Forecasted EPS | -$ 0.15 |
| Earnings Per Share (Surprise) | -$ 0.46 (-$ 0.31) |
| Last Year's EPS | -$ 0.19 |
| EPS YoY Change |
Out of the last 32 earnings reporting periods, Opus Genetics beat analysts’ expectations 6 times and fell short of expectations 15 time(s). Opus Genetics reported earnings per share of -$ 0.46 in the last report falling to reach an estimated EPS of -$ 0.15 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 10, 2026 | -$ 0.15 | -$ 0.46 | -$ 0.14 | |
| Aug 6, 2026 | -$ 0.16 | -$ 0.14 | -$ 0.25 | |
| May 21, 2026 | -$ 0.16 | -$ 0.19 | -$ 0.12 | |
| May 12, 2026 | -$ 0.16 | -$ 0.75 | -$ 0.24 | |
| Mar 10, 2026 | -$ 0.11 | -$ 0.14 | -$ 1.27 | |
| Nov 12, 2025 | -$ 0.14 | -$ 0.25 | -$ 0.29 | |
| Aug 13, 2025 | -$ 0.25 | -$ 0.12 | -$ 0.30 | |
| May 15, 2025 | -$ 0.34 | -$ 0.24 | -$ 0.29 | |
| Mar 31, 2025 | -$ 0.34 | -$ 1.27 | -$ 0.22 | |
| Nov 12, 2024 | -$ 0.24 | -$ 0.29 | -$ 0.21 | |
| Aug 13, 2024 | -$ 0.25 | -$ 0.30 | $ 0.25 | |
| May 10, 2024 | -$ 0.11 | -$ 0.29 | -$ 0.24 | |
| Mar 9, 2024 | -$ 0.05 | -$ 0.22 | -$ 0.24 | |
| Mar 8, 2024 | -$ 0.05 | -$ 0.21 | -$ 0.28 | |
| Nov 13, 2023 | -$ 0.22 | $ 0.25 | -$ 0.28 | |
| Aug 11, 2023 | -$ 0.23 | -$ 0.24 | $ 1.58 | |
| Jun 30, 2023 | -$ 0.23 | -$ 0.24 | -$ 0.22 | |
| May 15, 2023 | -$ 0.15 | -$ 0.28 | -$ 0.22 | |
| Mar 31, 2023 | -$ 0.15 | -$ 0.28 | -$ 0.25 | |
| Dec 31, 2022 | - | $ 1.58 | -$ 0.35 |
Opus Genetics’s stock was trading at $ 4.20 on Nov 9, 2026 a day before the last earnings report was released.Following the release of the earnings report, IRD’s price increased to $ 4.31 on Nov 11, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 10, 2026 | -$ 0.46 | $ 4.20 | $ 4.31 | |
| Aug 6, 2026 | -$ 0.14 | $ 3.78 | $ 3.66 | |
| May 21, 2026 | -$ 0.19 | $ 4.44 | $ 4.26 | |
| May 12, 2026 | -$ 0.75 | $ 5.12 | $ 5.03 | |
| Mar 10, 2026 | -$ 0.14 | $ 4.77 | $ 5.01 | |
| Nov 12, 2025 | -$ 0.25 | $ 1.97 | $ 1.85 | |
| Aug 13, 2025 | -$ 0.12 | $ 1.11 | $ 1.18 | |
| May 15, 2025 | -$ 0.24 | $ 0.95 | $ 1.02 | |
| Mar 31, 2025 | -$ 1.27 | $ 1.01 | $ 0.91 | |
| Nov 12, 2024 | -$ 0.29 | $ 1.17 | $ 1.08 |
Opus Genetics released its most recent earnings reports in November 2026, August 2026, May 2026, May 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Opus Genetics missed analysts’ expectations during the last earnings period by
